MORE Australians living with cystic fibrosis (CF) can now access subsidised treatment, with Vertex Pharmaceuticals announcing an expanded reimbursement agreement for its CF treatment, TRIKAFTA (elexacaftor/tezacaftor/ivacaftor and ivacaftor).
From 01 Jul, the drug will be funded on the Pharmaceutical Benefits Scheme (PBS) for people with CF aged two years and older with at least one responsive CFTR mutation, including many ultra-rare mutations previously without a funded treatment option.
The announcement means around 45 Australians will, for the first time, gain access to a CFTR modulator, which is a treatment that addresses the underlying cause of CF rather than just managing symptoms.
These people were previously unable to access any modulator treatment.
"Vertex has been committed to the cystic fibrosis community for more than 20 years," said Vertex Pharmaceuticals Country Manager ANZ, Sabrina Barbic (pictured).
"Our goal has always been to ensure that all those who can benefit from our medicines get access as quickly as possible, no matter their age or genotype.
"This expanded PBS listing, which enables funded access to Trikafta for additional mutations, many of them ultra-rare, is testament to this," Barbic added.
The above article was sent to subscribers in Pharmacy Daily's issue from 24 Jun 25
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 24 Jun 25
